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Background: Many data are available on expansion protocols for mesenchymal stromal cells (MSCs) for both experimental set-
tings and manufacturing for clinical trials. However, there is a lack of information on translation of established protocols for
Good Manufacturing Practice (GMP) from validation to manufacturing for clinical application. We present the validation and
translation of a standardized pre-clinical protocol for isolation and expansion of MSCs for a clinical trial for reconstitution of
alveolar bone. Methods: Key parameters of 22 large-scale expansions of MSCs from bone marrow (BM) for validation were
compared with 11 expansions manufactured for the clinical trial “Jaw bone reconstruction using a combination of autologous
mesenchymal stromal cells and biomaterial prior to dental implant placement (MAXILLO1)” aimed at reconstruction of alve-
olar bone. Results: Despite variations of the starting material, the robust protocol led to stable performance characteristics of
expanded MSCs. Manufacturing of the autologous advanced therapy medicinal product MAXILLO-1-MSC was possible,
requiring 21 days for each product. Transport of BM aspirates and MSCs within 24 h was guaranteed. MSCs fulfilled quality
criteria requested by the national competent authority. In one case, the delivered MSCs developed a mosaic in chromosomal
finding, showing no abnormality in differentiation capacity, growth behavior or surface marker expression during long-term
culture. The proportion of cells with the mosaic decreased in long-term culture and cells stopped growth after 38.4 population
doublings. Conclusions: Clinical use of freshly prepared MSCs, manufactured according to a standardized and validated proto-
col, is feasible for bone regeneration, even if there was a long local distance between manufacturing center and clinical site. Sev-
eral parameters, such as colony forming units fibroblasts (CFU-F), percentage of CD34+ cells, cell count of mononuclear cells
(MNCs) and white blood cells (WBCs), of the BM may serve as a predictive tool for the yield of MSCs and may help to avoid
unnecessary costs for MSCmanufacturing due to insufficient cell expansion rates.Key Words: advanced therapy medicinal products, cell production, Good Manufacturing Practice, karyotyping, mesenchymal
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Mesenchymal stromal cells (MSCs) are well known for
their immunomodulatory [1,2] and regenerative poten-
tial and have shown their applicability as a promising
therapy for tissue regeneration, e.g., liver repair [3],
osteoarthritis [4] and bone regeneration [5]. With
more than one million procedures each year in Europe
[6], bone is the most transplanted tissue in humans
after blood. Bone losses of traumatic (e.g., non-union
fractures) or pathological origin (e.g., tumors or jaw-
bone cysts) are generally filled with an autologous bone
graft or autologous bone marrow. Autologous bone
transplantation is the gold standard therapy for bone
reconstitution in oral and maxofacial surgery [7]. For
this treatment, a piece of autologous bone is removed,
commonly from the crista iliaca, causing a second bone
defect in the patient with possible side effects like pain
or nerve damage at the site of bone harvesting [8]. In
addition, autologous bone therapy may fail, due to pre-
term transplant resorption [9,10]. MSCs have been
shown to be present in almost every tissue [11]. Due to
their limited number in tissues, MSCs have to be iso-
lated from the original tissue and expanded ex vivo in
clean rooms (class A in B) [1214].
Different protocols for Good Manufacturing Prac-
tice (GMP)-compliant isolation and expansion of MSCs
have been described previously [1521], but there is a
lack of information on the suitability of pre-clinical pro-
tocols for experimental settings and animal models and
their translation for GMP-compliant manufacturing of
MSCs for clinical trials. We present the validation and
translation of a standardized pre-clinical protocol [12]
for isolation and expansion of MSCs for a clinical trial
for reconstitution of alveolar bone (Jaw bone reconstitu-
tion using a combination of autologous mesenchymal
stem cells and biomaterial prior to dental implant place-
ment; MAXILLO-1 [EudraCT number 2012-003139-
30; ClinicalTrials.gov identifier NCT02751125]) as an
example for translation of manufacturing protocols for
clinical trials in other indications.
Expanded MSCs for clinical applications are
classified as an advanced therapy medicinal product
(ATMP) according to the European Medicines
Agency (EMA) regulation number 1394/2007 of the
European Commission (EC) [22].
In this study, we describe the translation of a previ-
ously established protocol for GMP-compliant large-
scale expansion of bone marrow (BM)-derived MSCs
[12] to produce clinical doses of 50100 million
MSCs for jawbone reconstruction prior to dental
implant surgery for 11 patients participating in the clin-
ical trial MAXILLO-1. The MSCs expanded accord-
ing to the GMP-compliant protocol used in this study
have previously been tested for their osteogenic in vivo
bone formation potential in pre-clinical models[23,24]. In these models, MSCs were immobilized
on a macro-microporous biodegradable, resorbable
biphasic calcium phosphate.
Minimal criteria for MSCs as defined by the Inter-
national Society for Cellular Therapy (ISCT) [25,26]
or modifications of these criteria [1214,27,28] are
required to define identity and describe impurities of
the ATMP. Release parameters for the ATMP may
vary and include microbial, endotoxin and myco-
plasma testing, tests for viability, clonogenicity, identity
and purity and functional tests, depending on the type
of clinical trial and the demands from national compe-
tent authorities.
For most clinical trials usingMSCs, the manufactur-
ing centers and clinical centers are two individual institu-
tions at distinct locations. In this study, a bi-directional
transportation lasting 1824 h was necessary to trans-
port BM aspirate from the clinical site to the
manufacturing center and to transport the ATMP back
to the clinical site. Part of this study was to analyze feasi-
bility of interaction between a clinical partner and a
manufacturing center over a long distance. Freezing
ATMP has been shown to be quite inefficient because
the recovery rate and clonogenicity [29] are reduced by
cryopreservation and the clinical center additionally has
to manipulate the MSCs, which may alter the intended
clinical dose. It is also not clear if and how quickly
MSCs recover their full therapeutic activity after thaw-
ing. In principle, cryopreservation of MSCs is possible
with loss of viability and clonogenicity, depending on
the freezing protocol [30]. Several publications showed
maintenance of cell viability, surface marker expression,
plasticity [31] and function of MSCs (e.g., in a retinal
ischemia/perfusion model) [32]. Viability of (adipose-
derived)MSCs after cryopreservation in animal-free for-
mulations may, however, be less than 72% and reduced
by more than 20% [29] as compared with pre-freezing
viability with a recovery of down to 62%. The viability
rate is similar to the one observed for pre-clinical studies
at 8˚C § 3˚C for transportation of MSCs expanded
according to the protocol used in this study [12,24].
Effects of changes on gene expression profiles by
freezing and thawing are still unclear [33]. The
occurrence of cryopreservation-induced apoptosis
[34] and of freeze/thaw and osmotic stress [35] can
be avoided when using non-cryopreserved cells. As
summarized by Galipeau [36], clinical trials with
human MSCs almost always use cryopreserved
cells, whereas in the pre-clinical animal models,
live, log phase of growth MSCs are used almost uni-
versally. It was important for this study to use non-
cryopreserved MSCs showing the full potential of
bone formation when stored and transported at 4˚C
within 24 h including transportation. When using
freshly produced, unfrozen MSCs for therapy, opti-
mization of transportation conditions is crucial.
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manufacturing site. In this study we also showed
that there is no necessity of a local association of
manufacturer and operator when MSCs are shipped
at 4˚C at conditions previously established in a pre-
clinical setting keeping the bone formation potential
of the shipped cells [23,24].Methods
Ethical approval and participating manufacturing and
clinical centers
BM (validation runs) was collected from volunteer
healthy donors after written informed consent was
obtained according to the Declaration of Helsinki and
approval by the Ethics Committee of Ulm University
(ethical approval numbers 21/10 and 24/11). The clini-
cal trial MAXILLO-1 (Jaw bone reconstruction using a
combination of autologous MSCs and biomaterial
prior to dental implant placement) was approved by
the Norwegian ethical committee (2013/1284/
REKvest) and by the Norwegian Medicines Agency
(13/12062-15). The clinical trial followed the Euro-
pean guidelines for advanced therapeutic medicinal
products. The EudraCT number of the trial was 2012-
003139-50 and the trial was incorporated in the data-
base ClinicalTrials.gov with the identifier NCT
02751125. The Institute for Clinical Transfusion med-
icine and Immunogenetics Ulm (Ulm, Germany,
authorization number DE_BW_01_MIA_2013_0040/
DE_BW:91_IKT Ulm) received BM aspirates from
the Section for Haematology, Department of Clinical
Science, University of Bergen at the Department of
Medicine, Haukeland University Hospital, Bergen,
Norway, and delivered the ATMP to the Institute of
Clinical Dentistry, University of Bergen, Norway.Donor screening
BM donors were screened as described in the bio-
medical research protocol for the prospective inter-
ventional phase 1 clinical trial MAXILLO-1. In
summary, donors were between 18 and 80 years
(both genders), with lateral (width 5 mm or less) or
vertical bone loss (focusing lateral bone loss) of the
mandible behind the canine tooth and endented (at
least one missing tooth) for more than 6 months in
the region requiring reconstitution, and in good gen-
eral health presenting with normal blood cell counts
and renal and hepatic function within normal limits.Isolation and shipping of BM
Aspiration of 25 mL (target) BM was performed in an
operating room from the iliac crest after local anesthesia.By a cutaneous point of puncture, two to three points of
puncture of the posterior iliac spine were made with a
trocar. BM was harvested by fraction of
2-4 mL in 20-mL syringes, prefilled with heparin (ratio-
pharm). The harvest, in its primary packaging, was laid
out in an isothermal box labeled according to Directive
2004/23/EC [37] and 2006/17/EC [38]. The transport
temperature was between 18˚C and 24˚C, with temper-
ature traceability. Delivery to the manufacturing centers
was ensured within 24 h by accompanied transportation
using a qualified transportation company.GMP-compliant isolation and expansion of MSCs
Isolation and expansion ofMSCs from the BM aspirates
was performed as previously described as two-step
protocol, option 1 (TSP1) by Fekete et al. [12]. The dif-
ferent steps of the manufacturing process, the corre-
sponding test parameters and the responsibilities are
summarized in Supplementary Table 1. Disposables,
reagents and excipients are listed in Supplementary
Table 2 and Supplementary Table 3. In brief, BM was
directly seeded without any further manipulation in
Minimal Essential Medium Eagle, alpha formulation
(alpha-MEM medium) supplemented with 5% platelet
lysate (PL) and 1 IU heparin/mL at a concentration of
50 000 BM white blood cells per cm2 in one to eight 2-
chamber CellStacks (Corning) at day 0 and incubated
at 5% CO2 atmosphere, 95% relative humidity at 37˚C.
After 24 days, the supernatant was discarded and
replaced by fresh alpha-MEM (Lonza) supplemented
with 5% PL (IKT Ulm) and 1 IU heparin/mL. Twice a
week, the supernatant was replaced by alpha-MEM sup-
plemented with 5% PL and 1 IU heparin/mL. At day
+14, the cells were rinsed with Dulbeccos Phosphate
Buffered Saline (DPBS, Lonza) and detached and
MSCs of passage (P) 0 (MSCP0) were harvested using
TrypZean (Lonza). Harvested cells were re-seeded at
the concentration of 4£ 103 MSCP0 per cm2 in alpha-
MEM medium supplemented with 8% PL and 1 IU
heparin/mL in one to seven 2-chamber CellStacks.
Twice a week, the supernatant was replaced by alpha-
MEM supplemented with 8% PL and 1 IU heparin/
mL. At day 21, the cells were rinsed with DPBS and
harvested using TrypZean. Cells were resuspended in a
5% albumin solution (CSL Behring) to obtain the final
product MAXILLO-1 on which quality controls were
applied. Cells were packaged and labeled for the ship-
ment to the clinical center at the University of Bergen.
All the materials and reagents used for the production
were selected due to their suitability during the valida-
tion process to ascertain their compliance to be used in
the manufacturing process. Specifications of the final
product were as described in Supplementary Table 4.
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BM aspirate was seeded in duplicates in T25 flasks
(Nunc Thermo Scientific) at the same cell density as
the main culture using the same culturing conditions.
For MSC of passage 0 (MSCP0), MSC of passage 1
(MSCP1) duplicates of 200 and 400 cells per T25
flask were seeded at the same culturing conditions as
the main culture. After 10 days, the medium was dis-
carded and cells were Giemsa-stained (Sigma) on
T25 flasks. Clonogenicity was assessed by counting
colonies consisting of more than 50 cells/colony.Differentiation capacity
Differentiation of MSCP1 was performed as described
previously in detail [12,13,3941], using the commer-
cially available kits for adipogenic (Lonza), chondro-
genic (Miltenyi Biotech) and osteogenic (Miltenyi
Biotech) differentiation.Quality controls: microbial testing, mycoplasma screening,
endotoxin testing, karyotyping and flow cytometry
Microbial testing was performed after matrix valida-
tion according to chapter 2.6.27 of the European Phar-
macopoeia (Ph Eur) 8.0 [42] using the BacT/ALERT
iAST aerobic and BacT/ALERT iNST anaerobic cul-
ture bottles (Supplementary Table 2) in a BacT/
ALERT 3D system (BioMerieux). Samples were
shipped to an accredited contract laboratory, the
Institute for Transfusion Medicine and Immunology,
Mannheim, Germany, for mycoplasma testing using
polymerase chain reaction (PCR) as previously
described [43] after matrix validation according to
chapter 2.6.7/2.6.21 of the Ph Eur 8.0 [42] and to
Labor L+S AG, Bad Bocklet-Groenbrach, Germany
for endotoxin testing by Limulus amebocyte lysate
(LAL) test after matrix validation according to chap-
ter 2.6.14 of the Ph Eur 8.0 [42].
For karyotyping, 100£ 103200£ 103 MSCP0
were seeded in 42 mL in a T175 flask (Nunc Thermo
Scientific) for 24 days until the cells reached
approximately 50% confluence. Colchizin (1.63 mL
of a 20 mg/mL solution from Eurobio) was added
and incubated at 5% CO2 atmosphere, 95% relative
humidity at 37˚C for at least 2 h. Cells were rinsed
once with 50 mL of DPBS, harvested by TrypZEAN
treatment, collected in 10 mL of complete medium
and transported within 2 h to the accredited contract
laboratory, the Institute for Human Genetics, Uni-
versity Hospital Ulm (Ulm, Germany), for karyotyp-
ing according to the national guidelines [44,45] and
the guidelines of the European Cytogeneticists Asso-
coation (E.C.A.) Permanent Working Group for
Cytogenetics and Society [46,47].Flow cytometry was performed as previously
described [12,13,28]. Approximately 1£ 1064£ 106
MSCP0 or MSCP1 were stained per assay. In brief,
cells were washed in DPBS and resuspended in 100mL
of DPBS. Cells were stained with a combination of
either immunoglobulin (Ig)G-fluorescein isothiocya-
nate (FITC) (20 mL, clone X40), IgG-phycoerythrin
(PE) (20 mL, clone X40) and IgG-peridinin chloro-
phyll protein (PerCP) (20 mL, clone X40), or CD90-
FITC (1 mL, clone 5E10), CD34-PE (20 mL, clone
8G12) and CD45-PerCP (20 mL, clone 2D1), or
CD105-FITC (10 mL, clone SN6), CD73-PE (20 mL,
clone AD2) and CD3-PE (20 mL, clone SK7), or
major histocompatibility complex class II (MHC cII)
human leucocyte antigen (HLA)-DQ,DP-DR-FITC
(20 mL, clone T€u39) and major histocompatibility
complex class I (MHC cI) HLA-A,B,C-PE (20 mL,
clone G46-2.6), respectively. Antibodies were pur-
chased from BD Bioscience, except CD105 (Bio-Rad
AbD Serotec GmbH). After 15 to 20 min of staining
at ambient temperature, cells were washed in DPBS
and the fluorescence intensity of 50 000 cells was
acquired using a FACScan with CellQuest 3.3 software
(BD Biosciences).Shipping of the ATMP
The transportation of freshly detached MSCs at
5˚C § 3˚C was performed with temperature trace-
ability. Delivery to the clinical center in Bergen was
ensured within 24 h using a qualified transporter
(World Courier [Deutschland] GmbH). Stability of
the ATMP in 5% saline solution has previously
been demonstrated [24].Statistical analysis
Statistical analysis was performed using GraphPad
Prism 7.01 Software for Windows. D’Agostino &
Pearson normality test was performed for each dataset
to test for normal distribution of data. In case of normal
distribution, data were compared using the unpaired t
test with Welch’s correction; for datasets not passing the
D’Agostino & Pearson normality test, data were
compared using the Mann-Whitney U test. Kruskal-
Wallis test was used for multiple-parameter analyses.
Differences were considered as significant for P < 0.01
because of multiple testing of the dataset. The correla-
tion betweenmultiple parameters was assessed, comput-
ing Spearman correlation (r values) for every pair of the
following datasets: time between end of aspiration and
end of seeding (h), age (y), aspiration volume (mL),
aspiration volume without heparin (mL), white blood
cell count ([WBC]/mL), mononuclear cell count
([MNC]/mL), % MNC of WBC, % CD34+ in BM
aspirate, harvest density of MSCP0 (cells/cm2), harvest
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MSCP0 (h), doubling time of MSCP1 (h), population
doublings in P0, population doublings in P1, cumulative
population doublings, CFU-F/106 BM-WBC, CFU-F/
106 MSCP0, CFU-F/106 MSCP1, MSCP0 harvested/
mL BM aspirate seeded and MSCP1 harvested/mL BM
aspirate seeded. Correlations with r  0.5 and P < 0.05
were considered as significant.Results
Donor characteristics
Overall, 13 aspirations were performed in the context
of the clinical trial MAXILLO-1 and 21 aspirations of
BM were performed for validation. Production of two
of the 13 aspirates for clinical trial MAXILLO-1 was
stopped at passage 0 for patients 1-05 and 1-10
because the overall harvest of 0.9£ 106 and 1.2£ 106
cells in passage 0 was not sufficient to start passage 1.
In accordance with this, no CFU-F/106 BM-WBCs
were detected (data not shown). One BM from the
validation was split (identification [ID] 7585) and two
BM aspirates from patients within MAXILLO-1 had
to be discarded (ID 1-05 and 1-10) due to lack of
CFU-F in the aspirate and growth of the culture dur-
ing the passage 0 growth phase (data not shown).
Information on shipping and donor characteristics are
presented in Supplementary Table 5 and Supplemen-
tary Figure 1 and summarized in Table 1.
The group of volunteer healthy donors and
MAXILLO-1 patients differed significantly in age
(P < 0.0001). Significant differences were also
observed for clonogenicity of the BM aspirate (CFU-
F/106 BM-WBC; P= 0.0060), time between end of
aspiration and beginning of seeding, WBC/mL BM
aspirate (P < 0.0001) and MNC/mL BM aspirate
(P < 0.0001), whereas aspiration volumeTable 1. Information on BM aspirates from validation runs (A) and ma
BM aspirate, WBC count/mL BM aspirate and number of CFU-F of BM
(A) Validation runs











SD, standard deviation.(P= 0.2414) and the percentage of CD34 cells in the
aspirate (P= 0.0946) did not significantly differ.MSC isolation and expansion for validation
Detailed information on data for the expansions per-
formed is shown in Table 2, Figure 1, Supplemen-
tary Table 6 and Supplementary Table 7.Validation
For validation, BM-WBCs were seeded on 4307 §
2911 cm2 culture surface at a cell density of 49 961
§ 264 cells/cm2. The first culture step was 13.8 §
0.1 days and resulted in a density of passage 0 MSC
(MSCP0) of 25.7£ 103/cm2 § 15.7£ 103/cm2. This
corresponds with 13.1 § 0.8 population doublings
with a doubling time of 25.4 § 1.6 h. In the second
culture step, 4008 § 2 MSCP0/cm2 were seeded on
5753 § 3481 cm2 and cultured for an additional 6.9
§ 0.2 days. This culture resulted in a cell density of
passage 1 MSC (MSCP1) of 49.1£ 103/cm2 §
18.0£ 103/cm2. This corresponds with 3.5 § 0.7
population doublings with a doubling time of 51.7 §
24.1 h. The cumulative number of population
doublings was 16.6 § 1.
The overall harvest of the final product was
283.2£ 106 § 187.3£ 106. The calculated yield was
17.5£ 103 § 14.8£ 103 MSCP0/mL BM aspirate
and 230.6£ 103 § 245.3£ 103 MSCP1/mL BM
aspirate. This theoretically would have allowed a
total harvest of 4540.2£ 106 § 5227.9£ 109
MSCP1 from as little as 23.6 § 8.2 mL of BM aspi-
rate within 20.8 § 0.3 days, based on the assump-
tion that all BM-WBCs of the BM aspirate were
seeded in passage 0 and the total harvest of passage 0
was reseeded for passage 1.nufacturing for the clinical trial MAXILLO-1 (B): age, volume of
aspirate per million BMWBCs.










Table 2. Key information of expansion process for MSCs from validation runs (A) and manufacturing for the clinical trial MAXILLO-1 (B):
doubling time in passage 0, passage 1 and number of population doublings in passage 0 and passage 1 and number of cumulative population
doublings in passage 0 and passage 1, achieved overall harvest of the final product (MSC of passage 1), and calculated yield (MSC/mL BM
aspirate) of MSCs for passage 0 and passage 1.







(MSC x 103/mL BM
aspirate) for
Hypothetical maximum
harvest (cells x 106)
P0 (h) P1 (h) P0 P1 Cumulative (P0 and P1) P0 P1
Mean 25.4 51.7 13.1 3.5 16.6 283.2 17.5 230.6 4540.2
SD 1.6 24.1 0.8 0.7 1.1 187.3 14.8 246.3 5227.9
Minimum 21.8 38.7 11.7 1.2 14.4 11.9 0.5 6.6 13.6
Maximum 28.4 155.4 15.2 4.3 19.1 740.8 54.6 1012.1 20141.3
(B) MAXILLO-1 MSCs
Mean 25.3 49.3 13.4 3.4 16.8 273.7 5.3 63.2 1424.9
SD 2.5 4.4 1.4 0.3 1.5 104.5 5.0 69.1 1653.5
Minimum 20.5 44.1 11.1 2.9 14.5 53.3 0.5 5.3 103.8
Maximum 30.3 57.1 16.4 3.8 20.2 412.0 18.3 243.5 5905.4
The hypothetical maximum harvest indicates the maximum harvest that could have been achieved in case all aspirated BM was used for the
MSC isolation and expansion process.
P0, passage 0; P1, passage 1.
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From the MAXILLO-1 patients’ BM aspirates, BM
WBCs were seeded on 5493 § 2743 cm2 culture sur-
face at a density of 49 955§ 65 cells/cm2. The first cul-
ture step was 14.0 § 0.0 days and resulted in a density
of passage 0 MSC (MSCP0) of 13.4£ 103/cm2 §
7.0£ 103/cm2. This corresponds with 13.4§ 1.4 popu-
lation doublings with a doubling time of 25.3 § 2.5 h.
In the second culture step, 3882 § 374 MSCP0/cm2
were seeded on 6467 § 2132 cm2 and cultured for an
additional 7.0 § 0.0 days. This culture resulted in a
density of passage 1 MSC (MSCP1) of 42.7£ 103/cm2
§ 9.4£ 103/cm2. This corresponds with 3.4§ 0.3 pop-
ulation doublings with a doubling time of 49.3 § 4.4 h.
The cumulative number of population doublings was
16.8§ 1.5.
The overall harvest of the final product was
273.7£ 106 § 104.5£ 106. Thus, the clinical dose
of 2 x [50£ 106] MSCs could be produced in all
cases except for patient 1-07. For this patient, a sin-
gle dose of 50£ 106 MSC was produced, fulfilling
the specifications (Supplementary Table 4).
The calculated yield was 5.3£ 103 § 5.0£ 103
MSCP0/mL BM aspirate and 63.2£ 103 §
69.1£ 103 MSCP1/mL BM aspirate. This theoreti-
cally would have allowed a total harvest of
1424.9£ 106 § 1653.5£ 106 MSCP1 and produc-
tion of a minimum of two to a maximum of 118
doses of 50£ 106 MSCP1 from as little as 21.4 §
2.0 mL of BM aspirate within 21.0 § 0.0 days when
seeding all BM aspirate for passage 0 and all MSCP0
for generation of the ATMP.Statistical analysis
When isolating and expanding MSCs, no significant
differences of clinical relevant parameters between
the group of volunteer healthy donors and MAX-
ILLO-1 were observed for the parameters harvest
density (MSCs/cm2) of MSCP1 (P= 0.19463), yield
(MSCs harvested/mL BM aspirate seeded) of passage
0 (P= 0.0153) and passage 1 (P= 0.2134), popula-
tion doublings in passage 0 (P= 0.5247), in passage
1 (P= 0.7485) and cumulative population doublings
(P= 0.6553), doubling time during passage 0
(P= 0.3551) and passage 1 (P= 0.2484). There was
a significant difference in harvest density (MSCs/
cm2) of MSCP0 (P= 0.0048). This difference,
which disappears during further passaging, is
reflected by different CFU-F counts in the BM aspi-
rates and may be caused by differences in the trans-
portation time and age of donors in the group of
volunteer healthy donors and MAXILLO-1 patients.Quality controls
All quality controls were carried out according to the
Ph Eur (Supplementary Table 8) for the correspond-
ing method and all matrices have been validated for
the tests applied.Viability
Percentage of viable cells was 94.6% § 3.1% in the
BM aspirate (BM-MNC), 97.0% § 3.2% for MSCP0
Figure 1. Key parameters of cell expansion. (A) MSC harvesting density (cells harvested/cm2), (B) yield per mL BM aspirate seeded (MSCs/
mL BMaspirate) and (C) doubling times (doubling time [h]), are shown for passage 0 and passage 1 for expansions used for the validation
process and for the clinical trial MAXILLO-1. (D) Number of population doublings for MSCP0 and MSCP1 and the cumulative number
of populations doublings is shown for expansions used for the validation process and for the clinical trial MacilloCT-1. Grey bars show
mean and standard deviation. MSCP0, passage 0 MSC; MSCP1, passage 1 MSC; val, data for validation runs; Maxillo or Max, data for
clinical trial MAXILLO-1.
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(Table 3, Figure 2A and Supplementary Table 9).
ForMAXILLO-1 patients, the percentage of viable
cells was 92.5% § 3.5% in the starting material (BM-
MNC), 97.7% § 1.7% for harvested MSCP0 and
97.9% § 1.1%, for the ATMP MAXILLO-1 MSCs.
No significant difference in viability of cells from BM
(P=0.0767), of MSCP0 cells BM (P=0.8995) or
MSCP1 BM (P=0.0104) cells from volunteer healthy
donors and MAXILLO-1 patients was seen. The
Kruskal-Wallis test failed to reveal significant differ-
ence in viability of MSCP0 and MSCP1 between the
two groups of donors.Impurities and identity
The content of impurities of the starting material (i.
e,. leukocytes or hematopoietic stem cells was
determined by expression of CD3, CD34, CD45
and MHC cII on MSCP0; Table 4, Figure 2B and
Supplementary Table 10) and MSCP1 (Table 4,Figure 2B and Supplementary Table 11) cells using
flow cytometry. In summary, parameters for iden-
tity and impurity were fulfilled for all expansions
from both volunteer healthy donors and MAX-
ILLO-1 patients with one exception: MSCP1
expanded from volunteer healthy donor 7575
showed deviations for the parameters CD3 and
CD105. The percentage of CD3+ cells was 23.5%
(with an allowed threshold of 5%), and the
expression of CD105+ cells was 88.97% (with an
allowed threshold of 90%). Thus, only one prepa-
ration of 33 (i.e., 3%) did not fulfill the release
quality control criteria for identity and impurity.Clonogenicity (CFU-F)
Expanded MSCs showed a clonogenicity of
192£ 103 § 72£ 103 colonies/106 seeded MSCP0
and of 210£ 103 § 79£ 103 colonies/106 seeded
MSCP1 for cells from volunteer healthy donors
and of 171£ 103 § 86£ 103 colonies/106 seeded
Table 3. Percentage of viable cells in the starting material, for har-
vested passage 0 MSCs (% viable cells after harvest of P0) harvested
passage 1 MSCs (% viable cells after harvest of P1) from validation
runs (A) andmanufacturing for the clinical trial MAXILLO-1 (B).









Mean 94.6 97.0 94.5
SD 3.1 3.2 4.2
Minimum 87.0 86.2 84.7





Mean 92.5 97.7 97.9
SD 3.5 1.7 1.1
Minimum 86.9 94.4 93.3




Thresholds for release of the ATMPMAXILLO-1 are indicated at
the bottom of the table.
ND, not defined (declaration parameter only).
Translation of a GMP-compliant MSC protocol 475MSCP0 and of 91£ 103 § 40£ 103 colonies/106
seeded MSCP1 for cells from MAXILLO-1
patients. BM aspirates from volunteer healthy
donors differed significantly in their CFU-F
content (P = 0.0060) and MSCP1 showed
significant difference in clonogenicity (P = 0.0003;
Figure 2C). Interestingly, MSCP0 from volunteer
healthy donors and MAXILLO-1 patients did not
differ in their clonogenic potential (P = 0.3551).Differentiation capacity
Adipogenic, chondrogenic and osteogenic differentia-
tion capacity was shown for all expansions performed
for validation runs and in the context of MAXILLO-1.
Representative photographs are shown in Supplemen-
tary Figure 2. All batches of MSCs exhibited a multi-
potent capacity in the three lineages.Microbial, endotoxin and mycoplasma testing
Microbial testing of the starting material (BM), of the
cell culture supernatant at day 7, of MSCP0 and of
MSCP1 was negative for all expansions (Supplemen-
tary Table 12). Endotoxin testing was performed for all
expansion and mycoplasma testing was performed for
expansions in the context of the clinical trial MAX-
ILLO-1 and for 8 of the 22 cell expansions from volun-
teer healthy donors. For all tested products samples,
anaerobic and aerobic cultures showed a negative testresult. NomycoplasmaDNAwas detectable and endo-
toxin levels were1 IU/mL in all cases.Karyotyping
Karyotyping was set up for all 33 expansions. In one
case (ID 1-07), only an insufficient number of meta-
phases could be achieved (Supplementary Table 13).
A chromosomal change in only one metaphase could
be detected for validation run ID 7537, 7543, 7562
and 7574. From the occurrence of such abnormalities
no conclusion can be made on the culture.
In one case (ID 1-04), four different chromo-
somal changes of the active substance were observed
after release of the ATMP. The karyotype was as fol-
lows: 46,XX[29]; 46,XX,t(3;5;13)(p1?3;q33;p1)[6];
46,X,?inv(X)(p22q1?1[3]; and 46,X,+8[1]; 47,XX,
+21[1]. Two of the four changes occurred in more
than one metaphase. To exclude chromosomal insta-
bility, immortalization and any effect on growth reg-
ulation, long-term cultures were set up.Long-term culture of MSCs from patient 1-04
Cells were cultured in accordance with the expansion
protocol for 519 days and passaged as indicated in
Supplementary Table 14A. This process was contin-
ued until cells stopped growth. At each passage, the
number of population doublings, doubling time and
viability were determined. Karyotping of cells from
passage 1, 2, 4, 7 and 9 was performed. In addition,
identity of the cells by flow cytometry (Supplemen-
tary Table 14B) and adipogenic, chondrogenic and
osteogenic differentiation capacity (Supplementary
Figure 3) was assessed for cells of passage 4 and 7.
During long-term culture, cells with the chromo-
somal finding 46,X,?inv(X)(p22q1?1[3], 46,X,+8[1]
and 47,XX,+21[1] disappeared after one additional
passage, whereas cells with the karyotype 46,XX,t
(3;5;13)(p1?3;q33;p1) persisted until passage 7 (i.e.,
34.9 cumulative population doublings of the CFU-F
from BM) but the relative proportion of cells with this
marker decreased from 15% (passage 1) to 3% (passage
7). Cells seeded after nine passages stopped growth.
The culture was maintained for 98 days. During this
time, 38.4 population doublings occurred and the dou-
bling time increased from 26.4 h (passage 0) to 340.9 h
(passage 9). Viability was always >80% and flow
cytometry analysis showed that <5% of cells were posi-
tive for CD3, CD45, CD34 and MHC cI and >90%
of cells were positive for CD73, CD90 and CD105
(Supplementary Table 14B). All these were release cri-
teria for clinically applicable MSCs in MAXILLO-1.
Interestingly, expression of MHC cI decreased to
75.75% for passage 7 cells. Patient 1-04 was screened a
second time about half a year later with patient ID 1-11
Figure 2. Key parameters of quality controls. (A) Percentage of viable WBCs in the BM aspirate and of viable MSCP0 and MSCP1, (B)
results of flow cytometry analysis for identity (CD73, CD90, CD105 and MHC cI) and impurities (CD3, CD34, CD45 and MHC cII) of
MSCP0 and MSCP1 and (C) number of colony-forming units fibroblasts per 106 cells (CFU-F/106 cells) for MNCs from BM aspirates,
MSCP0 and MSCP1 are shown for expansions used for the validation process and for the clinical trial, respectively. Grey bars show mean
and standard deviation.
476 M.T.Rojewski et al.[48] and cells were produced for transplantation of
MSCs to the opposite mandibular site before dental
implantation. For this second expansion, karyotyping
was without findings. Overall, there was no evidence for
expansion of the clone with the cytogenetic marker and
no evidence for autonomous proliferation with appear-
ance of phenotypically abnormal cells.Statistical correlations
Statistical correlations were calculated based on all 33
expansions (both from volunteer healthy donors and
MAXILLO-1 patients). Spearman correlation matrix
for multiple-parameter analysis is shown in Supple-
mentary Table S15A, and the corresponding P value
matrix is shown in Supplementary Table 15B.
As expected, a high correlation between BM-
WBC count and BM-MNC count (r= 0.8436; P <
0.0001) and between the percentage of CD34+ cells
and BM-WBC (r= 0.5938; P= 0.0005) count and
BM-MNC count (r= 0.6351; P= 0.0002) was
observed because one of the inclusion criteria fortreatment of MAXILLO-1 patients was the absence
of hematopoietic disorders.
Effects of the parameters “age” and “transportation
time” cannot be deciphered because transportation
time for BM aspirates from elder donors (mainly
MAXILLO-1 patients) was significantly higher (see
donor characteristics) than transportation time for aspi-
rates from younger patients (volunteer healthy donors).
According to this, the correlation of age and transporta-
tion time was r=0.7719 (P < 0.0001). Both age and
transportation time show negative correlation with
WBC count, MNC count, percentage of CD34+ cells
in the BM aspirate, harvest density of MSCP0 (but not
MSCP1), CFU-F from BM aspirate and MSCP1 (but
not from MSCP0) and the yield of both MSCP0 and
MSCP1 harvested per microliter BM aspirate seeded
(for r and P values refer to Supplementary Table 15).
The percentage of CD34+ cells in BM aspirates
correlated with the number of CFU-F from the BM
aspirate (r=0.6288; P< 0.0002) and also with the har-
vesting density of MSCP0 (r=0.6586; P=0.0001). In
accordance with this, the number of CFU-F from the
Table 4. Flow cytometry in process quality control of passage 0 MSC and control of validation runs (A) and the ATMPMAXILLO-1 MSC (B).
(A) MSCs from validation runs
% Positive MSCs of passage 0 for indicated marker % Positive MSC of passage 1 for indicated marker
CD3 CD34 CD45 MHC cII CD73 CD90 CD105 MHC cI CD3 CD34 CD45 MHC cII CD73 CD90 CD105 MHC cI
Mean 0.07 -0.12 0.08 1.47 97.71 99.09 96.93 95.32 1.43 0.12 0.23 2.67 97.91 99.39 97.21 95.65
SD 0.44 0.38 0.28 1.21 1.18 0.73 1.95 4.88 5.07 1.11 0.77 3.14 1.07 0.98 2.67 2.78
Minimum -0.60 -1.34 -0.41 0.30 95.41 97.20 93.56 77.58 -0.90 -1.38 -0.76 -0.06 95.29 95.08 89.54 88.97
Maximum 1.06 0.53 0.80 4.60 99.49 99.80 99.36 99.45 23.51 4.74 3.39 14.02 99.43 99.89 99.72 99.41
Thresholds for in process controls of passage 0 cells Thresholds for controls of the ATMPMAXILLO-1 MSCs
20 20 20 ND 80 80 80 ND 5 5 5 ND 90 90 90 ND
(B) MAXILLO-1 MSCs
% Positive MSC of passage 0 for indicated marker % Positive MSC of passage 1 for indicated marker
CD3 CD34 CD45 MHC cII CD73 CD90 CD105 MHC cI CD3 CD34 CD45 MHC cII CD73 CD90 CD105 MHC cI
Mean -0.05 0.31 0.18 0.78 98.49 99.30 98.63 95.25 0.00 0.11 0.01 0,58 99.34 99.36 98.79 97.34
SD 0.42 0.23 0.16 0.82 0.72 0.52 0.79 8.60 0.23 0.13 0.18 1.07 0.10 0.07 0.37 1.26
Minimum -0.74 -0.14 -0.01 0.19 96.85 98.23 96.67 71.53 -0.39 -0.09 -0.25 -3.03 98.79 95.31 94.66 95.07
Maximum 0.64 0.71 0.52 2.68 99.25 99.69 99.47 99.02 0.44 0.29 0.18 3.27 99.56 99.87 99.98 98.72
Thresholds for in process controls of passage 0 cells Thresholds for controls of the ATMPMAXILLO-1 MSCs
20 20 20 ND 80 80 80 ND 5 5 5 ND 90 90 90 ND
Thresholds for release are indicated at the bottom of the table. Negative figures mean that the proportion of positive cells after staining with the respective specific antibody was lower than percent-
























478 M.T.Rojewski et al.BM aspirate correlated positively with the harvesting
density of MSCP0 (r=0.8016; P< 0.0001).
A positive correlation between WBC count in the
BM aspirates and MSCP0 cells (r=0.8522; P <
0.0001) and MSCP1 cells (r=0.7721; P < 0.0001)
harvested per microliter BM aspirate as well as between
MNC count in the BM aspirates and MSCP0 cells
(r=0.7865; P< 0.0001) andMSCP1 cells (r=0.7064;
P < 0.0001) harvested per microliter BM aspirate and
between the percentage of CD34+ cells in the BM aspi-
rates and MSCP0 cells (r=0.7195; P < 0.0001) and
MSCP1 cells (r=0.6163; P < 0.0001) harvested per
microliter BM aspirate was observed. The harvesting
density of MSCP0 correlated positively with the clono-
genicity of MSCP1 (r=0.5035; P=0.0143). For the
passage 1 culture step, there was a positive correlation
between harvesting density and number of population
doublings (r=0.9771; P < 0.0001) and, in accordance
with this, a negative correlation between harvesting den-
sity and doubling time (r= -0.9721; P < 0.0001). For
further correlations refer to Supplementary Table 15.Discussion
Production of cells
In this study, we have presented validation data of a
GMP-compliant protocol for MSC isolation and
expansion and have proven the feasibility of this proto-
col to manufactureMSCs for a clinical trial. Pre-clinical
studies (e.g., in the context of bone formation [15,49]
or osteoarthritis [4]) using non-cryopreserved MSCs
from BM or adipose tissue have been performed previ-
ously, but to our knowledge a systematic comparison of
data on growth behavior, yield and quality controls rele-
vant for release of the cell product (i.e., the manufac-
tured ATMP) obtained in the validation process and in
manufacturing of the clinical product has not been per-
formed before.
In this study we also have shown that the produc-
tion of clinical doses of MSCs for the clinical trial
MAXILLO-1 was possible from a remote production
site. Transport of BM aspirate from Bergen (Norway)
to Ulm (Germany) was possible within 24 h by using
a conventional courier service. The shelf life of 24 h
for freshly produced, non-cryopreserved, clinical-
grade MSCs was sufficient for release of the product
and transportation from the manufacturing site in
Ulm, Germany to the clinical site in Bergen, Norway,
where the product was implanted the day after. Before
starting the production of 11 clinical doses for jaw
augmentation, the production process was validated
using 22 expansions from BM aspirates of 21 volun-
teer healthy donors. The availability of volunteer
healthy BM donors is limited and, because the age of
patients treated within MAXILLO-1 was notpredictable prior to the recruitment of patients for the
clinical trial, the group of volunteer healthy donors
and MAXILLO-1 patients could not be matched for
parameters like gender, age, body mass index or
smoker status. Volunteer healthy donors had an aver-
age age of 26 years, and MAXILLO-1 patients had
an average age of 62 years. In addition, mean time
between end of aspiration and beginning of seeding
was 6.7 h for volunteer healthy donors and 22.3 h for
MAXILLO-1 patients. The high correlation for the
parameters “donor age” and “time between end of
aspiration and beginning of seeding” is caused by the
experimental setting of this study, because transporta-
tion time for BM aspirates from elder donors (mainly
MAXILLO-1 patients) was significantly higher than
transportation time for aspirates from younger
patients (volunteer healthy donors). Therefore, it is
not possible to decipher the reason for significant dif-
ferences of the two groups in clonogenicity of the BM
aspirate (CFU-F/106 BM-WBC), in WBC/mL BM
and in MNC/mL BM. Interestingly, the percentage of
CD34+ cells in the aspirates did not significantly dif-
fer. The percentage of CD34+ cells in BM aspirates
correlated with the number of CFU-F from the BM
aspirate. However, Kurt Yuksel et al. [50] showed no
correlation between the clonogenic potential of stro-
mal cells (CFU-F) and hematopoietic cells (colony
foming units granulocyte-macrophage; CFU-GM)
for patients with hematologic malignancies, patients
with a diagnosis of BM failure and patients without
hematologic disease. Both, CD34+ cells in BM aspi-
rates as well as CFU-F from the BM aspirate corre-
lated with the harvesting density of MSCP0.
Obviously, a high percentage of CD34-positive cells
and/or high CFU-F count and/or high cell count of
MNCs and/or WBCs in the BM aspirate also posi-
tively correlate with the yield of not only MSCP0, but
alsoMSCP1. Because BM cell count and also the per-
centage of CD34+ cells can easily be assessed at the
day of BM harvest, it may be possible to predict
whether a determined cell target of MSCP1 can be
achieved from each individual aspirate. Analysis of a
higher number than 33 large-scale expansions and
analysis of an independent set of expansions is neces-
sary to calculate the positive predictive value and the
validity of the above-mentioned assumption. Starting
from only 23 mL of BM aspirate, a total harvest of
13.6£ 106  20 141.3£ 106 to MSCP1 within 21
days would have been possible when using the whole
BM aspirate for cell expansion. This range of the
hypothetical overall yield shows the necessity to screen
for early available, reliable prediction parameters for
calculation of the expectable yield. In the setting of
large-scale manufacturing for clinical use, an appro-
priate cell number for seeding passage 0 has to be
used, sufficient to guarantee the target dose of the
Translation of a GMP-compliant MSC protocol 479respective clinical protocol, but not causing an
“overproduction,” taking account of economic issues.
Because published expansion protocols show a high
variability, we compared the doubling times in this
study with the doubling times from publications using
a similar expansion protocol [51,52]. We obtained
mean doubling times of about 25 h for cells in passage
0 and of about 39 and 44 h for passage 1 (Table 2).
These doubling times are comparable to the ones pub-
lished by Schallmoser et al. [52] (doubling time: 25 to
34 h, and calculated from available data: 10.5 popula-
tion doublings in 1115 days) and by Schallmoser et
al. [51] (doubling time: 36 to 89 h, and calculated
from available data: 2.76.7 population doublings in
10 days; doubling time: 36 for comparable seeding
density to the protocol in this study).
It is also important to mention that the harvesting
density of MSCP0 correlated positively with the clono-
genicity of MSCP1, indicating that a higher harvesting
density in passage 0 might have a beneficial effect on
clonogenicity of cells applied to the patient. For long-
term cultures for up to 39 population doublings, repli-
cative aging, induction of alkaline phosphatase, bone
sialoprotein, osteocalcin and collagen 1 have been
described [53]. It has been shown that donor age and
the number of cumulative population doublings impact
the quality of MSCs in long-term cultures [54,55].
Beane et al. [54] showed lower cell yields and impaired
adipogenesis with age in rabbits. Long-term cultured
BM-derived MSCs exhibited slower population dou-
blings, increased senescence and inferior chondrogenic
differentiation potential. It has previously been shown
that CFU-F content [29] and bone morphogenetic
protein 7 (BMP7) [32] secretion increased after cryo-
preservation. Comparisons of the CFU-F content after
different handling or harvest procedures of the tissue
[56,57], from different tissue sites [56] or from donors
with different malignancies [50] have been published,
but to our knowledge nothing is known so far about
the impact of seeding density of MSCs on their clono-
genicity or capacity to form CFU-F in the straight fol-
lowing passages. We did not observe any significant
correlation of harvesting density for passage 0 and the
clonogenicity of the harvested cells from this passage,
whereas Bartmann et al. [51] used a similar xenogenic-
free expansion system for MSCs and observed an
inverse correlation of seeding density toMSC prolifera-
tion and CFU-F frequency of the same passage.Quality controls and release of cells
All cell productions performed for the clinical trial
MAXILLO-1 fulfilled the release criteria accepted by
the Norwegian Medicines Agency (NoMA) for this
ATMP (Supplementary Table 4). During the valida-
tion process, cell marker surface expression of MSCP1expanded from volunteer healthy donor 7575 showed
deviations for the parameters CD3 and CD105. Over-
all, only one single expansion of 33 (i.e., 3%) failed to
pass quality controls for identity and impurities.Bone augmentation capacity of manufactured cells
MSCs isolated and expanded to the described protocol
showed in vivo bone formation potential. Seven MSC
preparations manufactured in the context of validation
were successfully used in combination with a biphasic
calcium phosphate biomaterial (BCP+) to induce
ectopic bone formation and bone regeneration of
induced critical size defects of the calvaria in immuno-
compromised mice [23]. Bone formation was observed
and human cells were detected in the freshly formed
bone. MSCs for the clinical trial MAXILLO-1 were
implanted into patients with severely atrophied mandib-
ular bone and successful augmentation of alveolar bone
was observed in all study participants and shown by his-
tology and X-ray microtomography (mCT) images [48].Karyotyping
We observed chromosomal abnormalities in 5 expan-
sions (Supplementary Table 13). These findings
occurred in 4 of 22 (i.e., 18%) and in 1 of 11 (i.e.,
9%) MSCP1 obtained from volunteer healthy donors
and MAXILLO-1 patients, respectively. However,
because only one metaphase was affected, this obser-
vation was considered as irrelevant; from the occur-
rence of such abnormalities no conclusion can be
made [4447,58,59]. Only in two cases (donor 7574
and patient 1-04), a specific finding occurred with
higher frequency. Long-term cultures were set up for
MSCP1 from patient 1-04 with a total culture time of
105 days to exclude chromosomal instability, immor-
talization and any effect on growth regulation. Cells
with the specific chromosomal finding 46,XX,t
(3;5;13)(p1?3;q33;p1) persisted until the culture
stopped growth. The percentage of affected cells
decreased from 15% to 3%. The release criteria for
identity, impurity and viability were fulfilled and adi-
pogenic, chondrogenic and osteogenic differentiation
potential of cells were fulfilled also for cells harvested
from long-term culture passage 4 and passage 7. Dur-
ing the long-term culture, doubling time constantly
increased until cells showed progressive growth arrest
after 38.4 population doublings.
The MSCP1 with a positive finding in karyotyping
were applied to the patient because results from karyo-
typing were available only after implantation. Notewor-
thy, the same patient was screened and included a
second time for MAXILLO-1. Different individual
patient IDs (1-04 and 1-11) were given for the two
independent treatments on the left and right
480 M.T.Rojewski et al.mandibular side. MSCP1 cells obtained in the second
production process showed a normal female karyotype.
No phenotypical abnormalities or changes in differenti-
ation capacity were seen at any time point analyzed, nei-
ther for ID 1-04 nor for ID 1-11. In long-term culture,
cells rather underwent senescent. This is in line with
the clinical observations on patients who received the
MAXILLO-1 MSCs and had an uneventful clinical
course up to now (last follow-upMay 2017) [48]. Over-
all, laboratory analysis and clinical observations of
patient 1-04 did not reveal evidence for unlimited pro-
liferation of the clonal population with a cytogenetic
marker.
The presence of cells with atypical findings in
karyotyping has previously been described for
MSCs in the context of clinical trials to prevent
acute graft-versus-host disease or to treat irradia-
tion-induced lesions [60]. In five of 20 (i.e., 25%)
cases, chromosomal abnormalities occurred and
775% of the cells were affected by aneuploidies,
independent from the culture protocol. These fre-
quencies are in accordance with our observations.
In all cases with chromosomal changes reported by
Tarte et al. [60], human telomerase reverse tran-
scriptase (hTERT) activity was not detectable using
quantitative PCR. A recent publication reports an
increase of hTERT activity and a high spontaneous
malignant transformation of BM-derived MSCs in
long-term cultures [61]. Transformation of MSCs
occurred in 45.8% of long-term cultures and MSCs
showed loss of expression of typical MSC markers
like CD73 and CD90, down-regulated expression
of CD105 and limited differentiation potential. We
did not observe these alterations in surface marker
expression and differentiation capacity, even in the
long-term cultures of MSCs from patient 1-04.
This difference may also be caused by different cul-
ture conditions. Røsland et al. [61] cultured cells in
medium supplemented with fetal calf serum. In our
study, cells were grown in a xenogenic free system
using human platelet lysate as a source for growth
factors. This difference may contribute to suppres-
sion of transformation and favor senescence. Never-
theless, the significance of karyotyping as quality
control parameter thus remains questionable.
Quantitative analysis of hTERT may be the quality
parameter of choice.Conclusions
In this study, we have shown that there is no need of
close proximity between manufacturing facility for
MSCs and the clinical center where the cells are
applied, even if cryopreservation has to be avoided and
freshly produced cells have to be shipped on wet ice.
We demonstrated that several parameters, like CFU-F,percentage of CD34+ cells, cell count of MNCs and
WBCs of the BM, may serve as predictive tools for the
yield of MSCs and thus may help to develop strategies
to avoid unnecessary costs for production of MSCs
due to insufficient cell expansion rates. Further investi-
gations may be necessary to interpret the physiological
and clinical impacts of the positive correlation between
harvesting density of MSCs from early passages with
low numbers of population doublings and the clonoge-
nicity in the straight following passages.Acknowledgments
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